RETATRUTIDE

Name: RETATRUTIDE 10mg
Brand: Synvex Peptide

10mgCAS 2381089-83-2

Lipidated triple agonist of the GIP, GLP-1 and glucagon receptors (LY3437943).

Peptide Calculator

Calculate reconstitution values for this 10mg vial.

Verify your vial

Enter the 6-character code from the card in your box.

For laboratory research use only. Not for human or veterinary consumption, diagnostic or therapeutic use. Handle in accordance with institutional safety procedures.

Product Overview

Scientific profile

RETATRUTIDE (LY3437943) is a 39-residue synthetic peptide engineered as a single-molecule agonist at three class B G-protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR).

Research Background

The backbone is derived from the GIP sequence and incorporates two α-aminoisobutyric acid (Aib) residues and an α-methyl-leucine to resist DPP-4 proteolysis. Lys17 carries a C20 fatty-diacid side chain attached through a γ-glutamic acid / AEEA linker, which promotes reversible albumin binding and an extended circulating half-life. Its pharmacology was first described by Coskun et al. (Cell Metabolism, 2022).

Areas of Investigation

Comparative incretin and glucagon receptor pharmacology, including receptor potency ratios and signalling bias
Energy expenditure and substrate utilisation in preclinical metabolic models
Hepatic lipid metabolism and glucagon-mediated pathways
Structure–activity relationships of lipidated multi-agonist peptides

Analytical Profile

Each batch is characterised by reverse-phase HPLC (purity) and electrospray mass spectrometry (identity). Supplied as a lyophilized solid for in-vitro and preclinical laboratory research.

Specifications